02196 FOSUN PHARMA
- 14.300
- -0.260-1.79%
FOSUN PHARMA News
Fosun Pharmaceutical Buys Back Nearly 3 Million Yuan Worth of Shares
On December 13, FOSUN PHARMA (02196.HK) spent HKD 2.6635 million to repurchase 0.1855 million shares.
Gelonghui reported on December 13 that FOSUN PHARMA (02196.HK) announced that on December 13, 2024, it would spend 2.6635 million Hong Kong dollars to repurchase 0.1855 million shares, with a repurchase price per share ranging from 14.3 to 14.46 Hong Kong dollars.
Fosun Pharma Boosts Equity in Key Funds
Express News | Shanghai Fosun Pharma - Ningbo Fuying Will Acquire Equity Interests of RMB200.00 of Fund
Shanghai Fosun Pharma's New Strategic Agreements With Fosun International
FOSUN PHARMA (600196.SH): The controlling subsidiary intends to increase its shareholding in the Fund.
On December 11, Gelonghui reported that FOSUN PHARMA (600196.SH) announced that its holding subsidiary Ningbo Fuying, as an LP of the Nanjing Fund, Dalian Star Future Fund, and Suzhou Angel Fund, signed transfer agreements with FOSUN High Technology regarding the Shareholding of several property interests in these funds. The total consideration for this Shareholding is 140.42 million yuan, which includes: (1) a proposed investment of 90.92 million yuan to acquire another LP share of the Nanjing Fund, for which FOSUN High Technology has already contributed 200 million yuan, accounting for about 25.09% of the total contributed amount of this fund (of which 11 million yuan has been paid in).
On December 9, Fosun Pharma (02196.HK) spent 4.36 million Hong Kong dollars to repurchase 306,000 shares.
Gelonghui, December 9th丨Fosun Pharma (02196.HK) announced that on December 9, 2024, it spent 4.36 million Hong Kong dollars to repurchase 0.306 million shares at a price of 14.1-14.5 Hong Kong dollars per share.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Shanghai Fosun Pharmaceutical Gets Drug Registration for Pertuzumab Biosimilar
Fosun Pharma (02196): Henlius has received approval from the National Medical Products Administration to conduct clinical trials for HLX22 in combination with trastuzumab and chemotherapy or trastuzumab in combination with chemotherapy for HER2-expressing
Fosun Pharma (02196) announced that its controlled subsidiary Henlius Biotech Co., Ltd. and...
Fosun pharma (600196.SH): Approval of clinical trial for injectable HLX43 pharmaceutical.
On December 4th, Gelonghui reported that Fosun Pharma (600196.SH) announced that its controlled subsidiary Henlius Biotechnology Co., Ltd. and its controlled subsidiaries (hereinafter referred to as "Henlius") recently received approval from the National Medical Products Administration to conduct phase Ib/II clinical trials for HLX43 (a targeted PD-L1 antibody-novel DNA topoisomerase I inhibitor conjugate, hereinafter referred to as "the new drug") as a monotherapy or in combination for the treatment of advanced/metastatic solid tumors. Henlius plans to carry out this in china (excluding Hong Kong, Macau, and Taiwan) once conditions are met.
Shanghai Fosun Pharmaceutical (Group)'s Blood Health Medication Gets NMPA's Nod
Fosun Pharma (02196) has had 20 million shares released from pledge by its controlling shareholder, Fosun High Technology.
Fosun Pharma (02196) announced that on December 3, 2024, the company received a notification from its controlling shareholder Fosun...
Fosun Pharma (02196.HK) subsidiary obtained pharmaceutical registration approval.
On December 3, Gelonghui reported that fosun pharma (02196.HK) announced that shanghai fosun pharma (Group) Co., Ltd. (hereinafter referred to as "the company") and shanghai henlius biotechnology Co., Ltd. and its holding subsidiaries (hereinafter collectively referred to as "henlius") have developed the Hanshuang (i.e., Shruvalumab injection, hereinafter referred to as "the pharmaceutical") combined with pemetrexed and carboplatin for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative that cannot be surgically removed.
fosun pharma (600196.SH): Taohong Siwu Granule has received the acceptance of pharmaceutical registration application.
Gelonghui December 3 | fosun pharma (600196.SH) announced that its holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. recently had the pharmaceutical registration application for Taohong Siwu Granules accepted by the National Medical Products Administration. This new drug is a Class 3 traditional chinese medicine, mainly used for nourishing blood, promoting blood circulation, and removing blood stasis, intended for the syndrome of blood deficiency and blood stasis, with symptoms such as irregular menstruation, blood clots, sticky purple complexion, abdominal pain, and bloating. The prescription of this new drug is based on the Taohong Siwu Decoction from the Qing Dynasty's Chai Dehua's "Gynecology Ice Mirror", and has been included in the first batch of the "Catalog of Ancient Classic Prescriptions" by the State Administration of traditional chinese medicine.
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
No Data
